May 19, 2016
Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries
Video Categories: 2018 ASCO Insights, Biomarkers, and Video LibraryDr Sanjiv Agarwala argues that much of the biomarker data in melanoma presented at ASCO 2018 are around the value of PD-L1 testing; however, even PD-L1–negative melanoma patients seem to respond to anti–PD-1 therapy, although some studies suggest PD-L1–negative patients may be better candidates for combination immunotherapy.
Related Videos
October 28, 2014
Success of Cytoreductive Therapy
Listen as Dr. Mesa presents his opinion on the success of cytoreductive therapy with patients with polycythemia vera.Supported through funding from Incyte
October 28, 2014
Approaches of Therapy for PV Treatment
Ruben A. Mesa, MD, Mayo Clinic, Scottsdale Arizona describes why the need for cytoreductive therapy is evolving Supported through funding from Incyte